Re­gen­eron, Sanofi post good PhI­II asth­ma da­ta for Dupix­ent — but it’s los­ing its ha­lo

Just days af­ter As­traZeneca and Am­gen man­aged to catch an­a­lysts sleep­ing with a promis­ing new asth­ma drug called teze­pelum­ab, Re­gen­eron and Sanofi are com­ing in with new da­ta for Dupix­ent (dupilum­ab) which they are bet­ting will pave the way to a new ap­proval next year.

But sev­er­al an­a­lysts are say­ing Mon­day morn­ing that the new da­ta are a step down from the ex­cit­ing mid-stage re­sults these two ma­jor league part­ners put up. And they’re won­der­ing whether Dupix­ent — a one-time dar­ling — can live up to some old ex­pec­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER